Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.
Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Eder JP, et al. Among authors: doroshow db. JCO Precis Oncol. 2021 Nov;5:466-472. doi: 10.1200/PO.20.00247. JCO Precis Oncol. 2021. PMID: 34994649 Free PMC article. Clinical Trial.
BET inhibitors: a novel epigenetic approach.
Doroshow DB, Eder JP, LoRusso PM. Doroshow DB, et al. Ann Oncol. 2017 Aug 1;28(8):1776-1787. doi: 10.1093/annonc/mdx157. Ann Oncol. 2017. PMID: 28838216 Free article. Review.
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Mahdi H, et al. JCO Precis Oncol. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34527850 Free PMC article. Clinical Trial.
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder JP, Galsky MD, Marron TU, Smith CB, LoRusso PM, Hofstatter E, Doroshow DB. Blanter J, et al. Among authors: doroshow db. JCO Oncol Pract. 2024 Dec 11:OP2400293. doi: 10.1200/OP.24.00293. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39661920
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, Choueiri TK. Ürün Y, et al. Among authors: doroshow db. JCO Glob Oncol. 2020 Aug;6:1248-1257. doi: 10.1200/GO.20.00300. JCO Glob Oncol. 2020. PMID: 32755479 Free PMC article.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
48 results